Back to GILD Overview
NMS · Valuation Lab
GILD
Gilead Sciences, Inc.
Last$131.76
Market cap163.6B
EV/EBITDA11.9x
Intrinsic value
$191.80
MoS +31.3% · Undervalued
Assuming 26.7% FCF margin and 4.4% Y1–5 growth.
Upside to price
EV (DCF)250.5B
Terminal share72%
Expected IV$188.28
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 72% of EV
PV of stage FCFs71B
PV of terminal value179.5B
Enterprise value250.5B
Net cash / (debt)-12.4B
Equity value238.1B
Intrinsic value / share$191.80
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 31B | 8.3B | 7.8B | 94.3% |
| Y2 | 32.4B | 8.7B | 7.7B | 89.0% |
| Y3 | 33.8B | 9B | 7.6B | 84.0% |
| Y4 | 35.3B | 9.4B | 7.5B | 79.2% |
| Y5 | 36.9B | 9.8B | 7.4B | 74.7% |
| Y6 | 37.7B | 10.1B | 7.1B | 70.5% |
| Y7 | 38.5B | 10.3B | 6.8B | 66.5% |
| Y8 | 39.4B | 10.5B | 6.6B | 62.7% |
| Y9 | 40.2B | 10.7B | 6.4B | 59.2% |
| Y10 | 41.1B | 11B | 6.1B | 55.8% |
| Terminal | — | — | 179.5B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.